News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
497,289 Results
Type
Article (9965)
Company Profile (158)
Press Release (487165)
Multimedia
Podcasts (18)
Webinars (7)
Section
Business (171240)
Career Advice (365)
Deals (26339)
Drug Delivery (15)
Drug Development (54226)
Employer Resources (22)
FDA (9932)
Job Trends (8944)
News (244004)
Policy (18340)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (592)
Accelerated approval (24)
ADA (21)
Adcomms (1)
Allergies (100)
Alliances (34408)
ALS (109)
Alzheimer's disease (1010)
Antibody-drug conjugate (ADC) (297)
Approvals (10532)
Artificial intelligence (355)
ASCO (166)
Autoimmune disease (215)
Automation (32)
Bankruptcy (269)
Best Places to Work (7140)
BIO (41)
Biologics (2)
BIOSECURE Act (3)
Biosimilars (127)
BioSpace Insights (27)
Biotechnology (99)
Bladder cancer (141)
Brain cancer (33)
Breast cancer (519)
Cancer (3805)
Cardiovascular disease (226)
Career advice (296)
Career pathing (2)
CAR-T (186)
CDC (2)
Celiac Disease (1)
Cell therapy (522)
Cervical cancer (38)
Clinical research (48844)
Collaboration (1368)
Commercialization (3)
Company closure (4)
Compensation (1479)
Complete response letters (35)
COVID-19 (891)
CRISPR (69)
C-suite (828)
Cystic fibrosis (90)
Data (5802)
Denatured (10)
Depression (110)
Dermatology (62)
Diabetes (358)
Diagnostics (4325)
Digital health (39)
Diversity (2)
Diversity, equity & inclusion (4)
Drug discovery (186)
Drug pricing (17)
Drug shortages (2)
Duchenne muscular dystrophy (186)
Earnings (74357)
Editorial (6)
Employer branding (3)
Employer resources (20)
Events (89238)
Executive appointments (756)
FDA (12599)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (1048)
Gene editing (142)
Generative AI (12)
Gene therapy (359)
GLP-1 (347)
Government (1062)
Grass and pollen (2)
Guidances (285)
Healthcare (9534)
Hematology (95)
HIV (54)
Huntington's disease (24)
IgA nephropathy (66)
Immunology and inflammation (135)
Immuno-oncology (69)
Indications (158)
Infectious disease (1096)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (89)
Intellectual property (263)
Interviews (47)
IPO (12590)
IRA (8)
Job creations (2139)
Job search strategy (281)
JPM (5)
Kidney cancer (20)
Labor market (12)
Layoffs (106)
Leadership (3)
Legal (5293)
Licensing (8)
Liver cancer (48)
Longevity (19)
Lung cancer (526)
Lymphoma (257)
Machine learning (30)
Management (7)
Manufacturing (574)
Marketing (8)
MASH (122)
Medical device (8743)
Medtech (8887)
Mergers & acquisitions (14798)
Metabolic disorders (754)
mRNA (65)
Multiple sclerosis (106)
NASH (4)
Neurodegenerative disease (240)
Neuropsychiatric disorders (50)
Neuroscience (1928)
NextGen: Class of 2026 (3342)
Non-profit (961)
Now hiring (15)
Obesity (249)
Opinion (30)
Ovarian cancer (161)
Pain (178)
Pancreatic cancer (212)
Parkinson's disease (211)
Partnered (15)
Patents (488)
Patient recruitment (523)
Peanut (32)
People (42890)
Pharmaceutical (31)
Pharmacy benefit managers (8)
Phase 1 (15916)
Phase 2 (21883)
Phase 3 (14747)
Pipeline (7515)
Policy (34)
Postmarket research (1581)
Preclinical (6734)
Press Release (34)
Prostate cancer (191)
Psychedelics (12)
Radiopharmaceuticals (199)
Rare diseases (622)
Real estate (3256)
Recruiting (10)
Regulatory (15207)
Reports (25)
Research institute (684)
Resumes & cover letters (53)
Rett syndrome (41)
RNA editing (8)
RSV (51)
Schizophrenia (111)
Series A (192)
Series B (139)
Service/supplier (5)
Sickle cell disease (64)
Special edition (3)
Spinal muscular atrophy (89)
Sponsored (6)
Startups (2289)
Stomach cancer (5)
Supply chain (52)
Tariffs (2)
The Weekly (8)
Vaccines (364)
Venture capital (37)
Weight loss (95)
Women's health (82)
Worklife (1)
Date
Today (54)
Last 7 days (316)
Last 30 days (1727)
Last 365 days (19835)
2026 (12749)
2025 (20004)
2024 (23638)
2023 (27240)
2022 (35532)
2021 (38230)
2020 (34498)
2019 (24026)
2018 (18176)
2017 (19378)
2016 (18546)
2015 (24834)
2014 (22070)
2013 (18601)
2012 (20698)
2011 (20858)
2010 (20703)
Location
Africa (251)
Alabama (76)
Alaska (2)
Arizona (309)
Arkansas (11)
Asia (19030)
Australia (2290)
California (12281)
Canada (3191)
China (583)
Colorado (490)
Connecticut (417)
Delaware (212)
Europe (27287)
Florida (1803)
Georgia (381)
Hawaii (4)
Idaho (47)
Illinois (722)
India (55)
Indiana (323)
Iowa (15)
Japan (409)
Kansas (111)
Kentucky (31)
Louisiana (29)
Maine (26)
Maryland (1221)
Massachusetts (8057)
Michigan (312)
Minnesota (572)
Mississippi (5)
Missouri (85)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (63)
New Jersey (2668)
New Mexico (12)
New York (2845)
North Carolina (1294)
North Dakota (4)
Northern California (6175)
Ohio (292)
Oklahoma (15)
Oregon (19)
Pennsylvania (2266)
Puerto Rico (21)
Rhode Island (31)
South America (424)
South Carolina (76)
South Dakota (1)
Southern California (5059)
Tennessee (126)
Texas (1984)
United States (39693)
Utah (364)
Vermont (1)
Virginia (159)
Washington D.C. (41)
Washington State (983)
West Virginia (2)
Wisconsin (85)
Wyoming (1)
497,289 Results for "neurocrine biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day for the Prader-Willi syndrome community.
August 12, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
July 24, 2026
·
4 min read
Press Releases
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
July 22, 2026
·
6 min read
Press Releases
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
July 30, 2026
·
21 min read
Press Releases
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
July 10, 2026
·
2 min read
Press Releases
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
May 18, 2026
·
10 min read
Press Releases
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
August 7, 2026
·
6 min read
Press Releases
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June 2026
May 26, 2026
·
1 min read
Press Releases
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 6, 2026
·
18 min read
Press Releases
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
May 5, 2026
·
1 min read
1 of 49,729
Next
